AbbVie has announced the availability in Ireland of upadacitinib, an oral, selective and reversible Janus Kinase (JAK) inhibitor. It is for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1 This is now available to prescribe via the HSE-Medicines Management Programme under a HSE-Managed Access Protocol.**13
On August 24 last, the European Commission (EC) approved a recommended dose of upadacitinib for atopic dermatitis in adults. This is of 15 mg or 30 mg once daily based on individual patient presentation. 15 mg once daily for adolescents (12-17 years of age) and adults 65 years and older.1 Upadacitinib can be used with or without topical corticosteroids (TCS).1
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
